» Articles » PMID: 29560733

Novel [(3-indolylmethylene)hydrazono]indolin-2-ones As Apoptotic Anti-proliferative Agents: Design, Synthesis and in Vitro Biological Evaluation

Overview
Specialty Biochemistry
Date 2018 Mar 22
PMID 29560733
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

On account of their significance as apoptosis inducing agents, merging indole and 3-hydrazinoindolin-2-one scaffolds is a logic tactic for designing pro-apoptotic agents. Consequently, 27 hybrids (6a-r, 9a-f and 11a-c) were synthesised and evaluated for their cytotoxicity against MCF-7, HepG-2 and HCT-116 cancer cell lines. SAR studies unravelled that N-propylindole derivatives were the most active compounds such as 6n (MCF-7; IC=1.04 µM), which displayed a significant decrease of cell population in the G2/M phase and significant increase in the early and late apoptosis by 19-folds in Annexin-V-FTIC assay. Also, 6n increased the expression of caspase-3, caspase-9, cytochrome C and Bax and decreased the expression of Bcl-2. Moreover, compounds 6i, 6j, 6n and 6q generated ROS by significant increase in the level of SOD and depletion of the levels of CAT and GSH-Px in MCF-7.

Citing Articles

Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases.

Elagawany M, Abdel Ghany L, Ibrahim T, Alharbi A, Abdel-Aziz M, El-Labbad E J Enzyme Inhib Med Chem. 2024; 39(1):2311157.

PMID: 38348846 PMC: 10866054. DOI: 10.1080/14756366.2024.2311157.


Mechanistic insight and structure activity relationship of isatin-based derivatives in development of anti-breast cancer agents.

Singh A, Singh K, Sharma A, Sharma S, Batra K, Joshi K Mol Cell Biochem. 2023; 479(5):1165-1198.

PMID: 37329491 DOI: 10.1007/s11010-023-04786-0.


1-Benzyl-5-bromo-3-hydrazonoindolin-2-ones as Novel Anticancer Agents: Synthesis, Biological Evaluation and Molecular Modeling Insights.

Al-Warhi T, Almahli H, Maklad R, Elsayed Z, El Hassab M, Alotaibi O Molecules. 2023; 28(7).

PMID: 37049966 PMC: 10096524. DOI: 10.3390/molecules28073203.


Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents.

Khalil A, El-Moselhy T, El-Bastawissy E, Abdelhady R, Younis N, El-Hamamsy M J Enzyme Inhib Med Chem. 2023; 38(1):2157411.

PMID: 36629449 PMC: 9848300. DOI: 10.1080/14756366.2022.2157411.


Dependence on linkers' flexibility designed for benzenesulfonamides targeting discovery of novel hCA IX inhibitors as potent anticancer agents.

Tawfik H, Belal A, Abourehab M, Angeli A, Bonardi A, Supuran C J Enzyme Inhib Med Chem. 2022; 37(1):2765-2785.

PMID: 36210545 PMC: 9559471. DOI: 10.1080/14756366.2022.2130285.


References
1.
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D . New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990; 82(13):1107-12. DOI: 10.1093/jnci/82.13.1107. View

2.
Aggarwal B, Ichikawa H . Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle. 2005; 4(9):1201-15. DOI: 10.4161/cc.4.9.1993. View

3.
Sirisoma N, Pervin A, Drewe J, Tseng B, Xiong Cai S . Discovery of substituted N'-(2-oxoindolin-3-ylidene)benzohydrazides as new apoptosis inducers using a cell- and caspase-based HTS assay. Bioorg Med Chem Lett. 2009; 19(10):2710-3. PMC: 7126024. DOI: 10.1016/j.bmcl.2009.03.121. View

4.
Lee S, Abdelrahim M, Yoon K, Chintharlapalli S, Papineni S, Kim K . Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth. Cancer Res. 2010; 70(17):6824-36. PMC: 2988472. DOI: 10.1158/0008-5472.CAN-10-1992. View

5.
Eldehna W, Almahli H, Al-Ansary G, Ghabbour H, Aly M, Ismael O . Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents. J Enzyme Inhib Med Chem. 2017; 32(1):600-613. PMC: 6010087. DOI: 10.1080/14756366.2017.1279155. View